Michael Gejl
Michael Gejl
Bestätigte E-Mail-Adresse bei farm.au.dk
Titel
Zitiert von
Zitiert von
Jahr
In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial
M Gejl, A Gjedde, L Egefjord, A Møller, SB Hansen, K Vang, A Rodell, ...
Frontiers in aging neuroscience 8, 108, 2016
1842016
Quantitative rates of brain glucose metabolism distinguish minimally conscious from vegetative state patients
J Stender, R Kupers, A Rodell, A Thibaut, C Chatelle, MA Bruno, M Gejl, ...
Journal of Cerebral Blood Flow & Metabolism 35 (1), 58-65, 2015
842015
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer’s disease–protocol for a controlled, randomized double-blinded trial
L Egefjord, M Gejl, A Møller, H Brændgaard, H Gottrup, O Antropova, ...
brain 12, 14, 2012
812012
Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes
M Gejl, HM Søndergaard, C Stecher, BM Bibby, N Møller, HE Bøtker, ...
The Journal of Clinical Endocrinology & Metabolism 97 (7), E1165-E1169, 2012
602012
Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease
RB Nielsen, L Egefjord, H Angleys, K Mouridsen, M Gejl, A Møller, ...
Alzheimer's & Dementia 13 (10), 1143-1153, 2017
592017
Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment
M Gejl, B Brock, L Egefjord, K Vang, J Rungby, A Gjedde
Scientific reports 7 (1), 1-10, 2017
512017
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia
M Gejl, L Egefjord, S Lerche, K Vang, BM Bibby, JJ Holst, A Mengel, ...
Journal of Cerebral Blood Flow & Metabolism 32 (12), 2146-2152, 2012
442012
Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes
AM Bak, L Egefjord, M Gejl, C Steffensen, CW Stecher, K Smidt, B Brock, ...
Expert opinion on therapeutic targets 15 (10), 1153-1162, 2011
352011
Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain
M Gejl, S Lerche, L Egefjord, B Brock, N Møller, K Vang, AB Rodell, ...
Frontiers in neuroenergetics 5, 2, 2013
292013
Differences between long-acting insulins for the treatment of type 2 diabetes
MG Jensen, M Hansen, B Brock, J Rungby
Expert opinion on pharmacotherapy 11 (12), 2027-2035, 2010
282010
Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs—a nested case–control study
M Gejl, J Starup-Linde, J Scheel-Thomsen, S Gregersen, P Vestergaard
International journal of cardiology 178, 292-296, 2015
262015
At the Centennial of Michaelis and Menten, Competing Michaelis–Menten Steps Explain Effect of GLP‐1 on Blood–Brain Transfer and Metabolism of Glucose
M Gejl, J Rungby, B Brock, A Gjedde
Basic & clinical pharmacology & toxicology 115 (2), 162-171, 2014
232014
Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron …
M Svart, LC Gormsen, J Hansen, D Zeidler, M Gejl, K Vang, J Aanerud, ...
PloS one 13 (2), e0190556, 2018
222018
Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo-or hypoglycemia
M Gejl, S Lerche, A Mengel, N Møller, BM Bibby, K Smidt, B Brock, ...
PLoS One 9 (1), e83758, 2014
182014
Glucagon-like peptide-1 analog, liraglutide, delays onset of experimental autoimmune encephalitis in lewis rats
B DellaValle, GS Brix, B Brock, M Gejl, AM Landau, A Møller, J Rungby, ...
Frontiers in pharmacology 7, 433, 2016
162016
Oral administration of sitagliptin activates CREB and is neuroprotective in murine model of brain trauma
B DellaValle, GS Brix, B Brock, M Gejl, J Rungby, A Larsen
Frontiers in pharmacology 7, 450, 2016
132016
Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial
M Gejl, A Gjedde, B Brock, A Møller, E van Duinkerken, HL Haahr, ...
Diabetologia 61 (3), 551-561, 2018
122018
Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial
M Nilsson, N Jensen, M Gejl, ML Bergmann, H Storgaard, M Zander, ...
Diabetologia 62 (10), 1948-1958, 2019
112019
Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries
M Bangshaab, A Gutierrez, KD Huynh, JS Knudsen, DDR Arcanjo, ...
British journal of pharmacology 176 (3), 386-399, 2019
102019
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
J Hansen, B Brock, HE Bøtker, A Gjedde, J Rungby, M Gejl
Reviews in Endocrine and Metabolic Disorders 15 (3), 219-231, 2014
102014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20